Tag Archives: fn-end

Where To Look For Cheap Stocks In 2015: CAPE Around The World

2014 was a lousy year for global value investors. Cheap markets, as measured by the cyclically-adjusted price/earnings ratio (“CAPE”) got even cheaper, while expensive markets got even pricier. (Note: the CAPE takes a ten-year average of earnings as a way of smoothing out the economic cycle and allowing for better comparisons over time.) I expect this to reverse in 2015. At some point – and I’m betting it could be as early as the first quarter – global market valuations should start to revert to their long term averages. That’s fantastic news if you’re invested in cheap foreign markets. It’s not such fantastic news if your portfolio is exclusively invested in high-CAPE American stocks. Let’s take a look at just how skewed the numbers are. The S&P 500 managed to produce total returns of 13.7% in 2014. But as quant guru Meb Faber pointed out in a recent blog post , globally, the median stock market posted a loss of 1.33%. The cheapest 25% of countries saw declines of 12.88%, while the most expensive markets actually gained 1.36%. I should throw out a couple caveats here. These were the returns of U.S.-traded single-country ETFs, which are priced in dollars, and not the national benchmarks. The strength of the U.S. dollar relative to virtually every other world currency last year was a major contributor to the underperformance of the rest of the world. All the same, it’s worth noting that we’re in uncharted territory here. As Faber noted in a recent tweet , U.S. stock valuations relative to foreign stock valuations closed 2014 at the highest spread over the past 30 years. Four out of the five biggest relative valuation gaps resulted in outperformance by foreign stocks the following year. The only exception was 2014. Let’s dig into the numbers. The CAPE for the S&P 500 is now 27.2. That’s a full 63.9% higher than the historical average of 16.6 , more expensive than at the 2007 peak, and close to the 1929 peak. The only time in U.S. history where the S&P 500 was significantly more expensive based on CAPE was during the peak of the 1990s tech bubble. Sure, the “fair” CAPE is going to be a little higher today than in decades past due to record low bond yields (all else equal, lower yields mean higher “correct” valuations). But I should point out that yields are even lower in most of Europe and Japan, yet valuations are significantly cheaper. So while low bond yields might partially explain why U.S. stocks are expensive relative to their own history, it doesn’t explain why the U.S. is expensive relative to the rest of the world. No matter how you slice it, U.S. stocks aren’t the bargain they were a few years ago. Research Affiliates calcuates that U.S. stocks are priced to deliver returns of about 0.7% over the next 10 years. Using a similar methodology, GuruFocus calculates an expected return of about 0.3% . I’ve driven home how expensive U.S. stocks are. Now, let’s take a look at other global markets. Here are the world’s markets as measured by the CAPE and sister valuation metrics cyclically-adjusted price/dividend (“CAPD”) cyclically-adjusted price/cash flow (“CAPCF”) and cyclically-adjusted price/book (“CAPB”). All figures reported in Meb Faber’s Idea Farm using original data from Ned Davis Research. Country CAPE CAPD CAPCF CAPB Average Rank Greece 2.8 6.5 1.5 0.4 1 Austria 7.3 21.6 3.0 0.7 3.75 Portugal 7.7 12.9 3.2 1.0 4.25 Hungary 5.9 23.0 3.0 0.9 4.75 Italy 9.6 16.6 3.7 0.9 5.25 Russia 5.2 29.8 3.5 0.8 7 Czech Republic 10.3 15.3 5.3 1.6 7.75 Poland 10.8 22.9 5.0 1.5 8.75 Brazil 10.0 23.2 6.4 1.5 9.25 Spain 11.6 19.4 5.7 1.6 10.25 Ireland 11.0 24.7 7.7 1.3 11 France 13.8 29.3 7.6 1.5 15 Norway 12.1 29.2 6.6 1.9 15 New Zealand 14.6 18.2 7.5 1.9 15.25 U.K. 12.1 26.9 8.1 1.9 17.25 Egypt 13.2 27.7 7.9 2.1 18.25 Turkey 11.3 39.5 8.0 1.9 19 Korea 12.4 73.3 7.3 1.5 19.25 Finland 14.5 24.3 8.6 2.1 19.75 Singapore 13.8 32.6 10.3 1.7 20 Belgium 14.6 30.3 9.4 1.8 20.25 Germany 15.8 37.8 7.8 1.8 21 Australia 15.7 22.8 11.3 2.1 23 Netherlands 15.5 35.9 10.1 2.1 24.75 Israel 14.8 38.8 11 1.9 25.5 China 14.3 43.3 9.2 2.2 25.75 Chile 17.4 40.9 10.2 1.9 26.25 Hong Kong 18.2 40.1 13.8 1.7 27.5 Peru 14.3 33 12.2 3.5 28.25 Japan 23.4 69 8.8 1.6 28.5 Taiwan 19.7 30.8 9.7 0 30.25 Thailand 17.8 41.6 11.5 2.9 31 Canada 19.2 45 10.5 2.4 31.5 Sweden 19.1 39.8 13.6 2.8 31.75 Malaysia 19 42.7 12.8 2.5 32 Colombia 23.1 43.7 18.8 2.2 36.25 South Africa 20.9 45.3 14.8 3.4 36.5 Switzerland 22.4 47.9 17.4 3.2 37.25 Mexico 22.6 73.6 12.4 3.6 38 Indonesia 20.9 52.6 14.3 5.0 38 U.S. 23.6 69.0 14.7 3.4 38.75 Philippines 26.1 65.9 16.1 3.9 40 Denmark 30 99.4 18.6 3.9 42.25 (Note: The U.S. figures use the MSCI U.S. index rather than the S&P 500, hence the difference in CAPE value.) We see some familar names on the list. Greece remains the world’s cheapest market by a wide margin. Of course, Greece is also in the middle of an election cycle that may well result in the country getting booted out of the eurozone. Interestingly, Russia is cheap following Western sanctions and the collapse in the price of oil, yet there are several far more stable countries that are cheaper, such as Austria, Portugal, Hungary and Italy. Two countries that I’ve liked for years based on valuation – Brazil and Spain – round out the top ten. To put things in perspective, the most expensive market on this list–Spain–trades at nearly a 60% discount to the U.S. market based on CAPE. Yes, Spain has its problems. Its economy is stuck in a slow-growth rut, and unemployment remains over 20%. But Spain is also home to some of the world’s finest multinationals, such as banks BBVA (NYSE: BBVA ) and Banco Santander (NYSE: SAN ), telecom giant Telefonica (NYSE: TEF ) and fashion retailer Inditex ( OTCPK:IDEXY ). There are different ways to use this data. You could buy and hold country ETFs, such as the Global X FTSE Greece 20 ETF (NYSEARCA: GREK ), the Market Vectors Russia ETF (NYSEARCA: RSX ) or the iShares MSCI Spain ETF (NYSEARCA: EWP ). Or you could go with a convenient one-stop shop like Faber’s Cambria Global Value ETF (NYSEARCA: GVAL ). GVAL is nice collection of cheap stocks from around the world. As of last quarter, GVAL’s largest country weightings were to Brazil, Spain and Israel. Disclosures: Long GVAL, EWP, BBVA, SAN, TEF This article first appeared on Sizemore Insights as Where to Look for Cheap Stocks in 2015: CAPE Around the World Disclaimer : This site is for informational purposes only and should not be considered specific investment advice or as a solicitation to buy or sell any securities. Sizemore Capital personnel and clients will often have an interest in the securities mentioned. There is risk in any investment in traded securities, and all Sizemore Capital investment strategies have the possibility of loss. Past performance is no guarantee of future results.

Can Pharma ETFs Continue Their Uptrend In 2015?

The pharmaceutical sector, which had been witnessing several tax inversion deals over the last few months, is not likely to go down this route given the Sep 2014 notice issued by the U.S. Department of the Treasury. New rules imposed by the Treasury Department make such cross-border deals unattractive — in fact, companies like AbbVie (NYSE: ABBV ), Auxilium (NASDAQ: AUXL ) and Salix (NASDAQ: SLXP ) backed off from such agreements. However, mergers and acquisitions (M&As) will continue to play a major role and are not showing any signs of slowing down. Auxilium, which terminated its merger agreement with QLT (NASDAQ: QLTI ), will be acquired by Endo in the first quarter of 2015. Other acquisition deals announced recently include the upcoming acquisition of Cubist (NASDAQ: CBST ) by Merck (NYSE: MRK ) and that of Avanir (NASDAQ: AVNR ) by Japanese firm, Otsuka ( OTC:OSUKF ). Meanwhile, small bolt-on acquisitions will continue. In-licensing activities and collaborations for the development of pipeline candidates have also increased significantly. Therapeutic areas attracting a lot of interest include oncology, central nervous system disorders, diabetes and immunology/inflammation. The hepatitis C virus (HCV) market is also attracting a lot of attention. Immuno-oncology has been a key focus area this year as these therapies have the potential to change the treatment paradigm for cancer. Restructuring activities are also gaining momentum as large pharma companies are looking to cut costs and streamline their operations. Most of these companies are re-evaluating their pipelines and discontinuing programs which do not have a favorable risk-benefit profile. Another recent trend is the divestment/monetization of non-core assets so that the companies may focus on their core areas of expertise. Biosimilars and emerging markets are also a focus area. New Products Gaining Traction New products are steadily gaining traction and contributing significantly to sales. Drugs like Tecfidera (multiple sclerosis), Sovaldi (HCV), Olysio (HCV) and Imbruvica (cancer) are off to a strong start and represent significant commercial potential. So far in 2014, important product approvals include Esbriet and Ofev (idiopathic pulmonary fibrosis), Harvoni (HCV), Plegridy (multiple sclerosis), Keytruda (melanoma), Otezla (active psoriatic arthritis) and Dalvance and Sivextro (skin infections). Pharma ETFs in Focus Highlighted below are some pharma ETFs – ETFs present a low-cost and convenient way to get a diversified exposure to the sector. Powershares Dynamic Pharmaceuticals ETF ( PJP ) PJP, launched in Jun 2005 by Invesco PowerShares, tracks the Dynamic Pharmaceuticals Intellidex Index. The fund covers only health care stocks. The top 3 holdings include Eli Lilly (NYSE: LLY ) (5.22%), Gilead (NASDAQ: GILD ) (5.19%) and Celgene (NASDAQ: CELG ) (5.14%). The total assets of the fund as of Dec 9, 2014 were $1,511.7 million representing 27 holdings. The fund’s expense ratio is 0.58% while dividend yield is 0.42%. The trading volume is roughly 140,267 shares per day. SPDR S&P Pharmaceuticals ETF ( XPH ) XPH, launched in Jun 2006, tracks the S&P Pharmaceuticals Select Industry Index. This ETF covers pharma stocks with the top 3 holdings being Avanir Pharmaceuticals (5.09%), Auxilium Pharmaceuticals (4.52%) and Impax Laboratories (NASDAQ: IPXL ) (4.04%). Total assets as of Dec 9, 2014 were $1,114.72 million representing 35 holdings. The fund’s expense ratio is 0.35% and dividend yield is 0.57%. The trading volume is roughly 48,791 shares per day. iShares U.S. Pharmaceuticals ( IHE ) IHE, launched in May 2006, seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index. The fund mainly consists of pharma companies (88.38%). Biotech companies account for about 11.53% of the fund. The top 3 holdings of this fund are large-cap pharma companies are Johnson & Johnson (NYSE: JNJ ) (9.22%), Pfizer (NYSE: PFE ) (8.12%) and Merck 7.21%). The total assets of the fund as of Dec 9, 2014 were $850.8 million representing 43 holdings. The fund’s expense ratio is 0.43% with the dividend yield being 1.15%. The trading volume is roughly 30,863 shares per day. Market Vectors Pharmaceutical ( PPH ) PPH was launched in Dec 2011 and tracks the Market Vectors U.S. Listed Pharmaceutical 25 Index. The top 3 holdings of this fund are large-cap pharma companies – Johnson & Johnson (10.73%), Novartis (NYSE: NVS ) (9.73%) and Pfizer (7.64%). The total assets as of Dec 10, 2014 were $354.8 million representing 26 holdings. While the expense ratio is 0.35%, dividend yield is 1.54%. The trading volume is roughly 166,369 shares per day. Conclusion The worst of the patent cliff is over for the pharma sector which is slowly but steadily recovering from the impact of genericization. The NYSE ARCA Pharmaceutical Index is up 19.3% over the last year. Many companies, which had been struggling to post growth in the face of genericization over the past few years, are now on the recovery path. New products should start contributing significantly to results, and increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector.

Is 2015 The Year For Municipal Bond ETFs?

The U.S. muni bonds market had a great 2014 with its returns just below the S&P 500 and the Dow Jones Industrial Average. These two blue chip indices advanced a respective 15.3% and 11.5%. With the S&P 500 also crossing the 2,000 mark, muni bonds turned out to be the third best performing category gaining 8.7% (per Wall Street ), its three -year best. Needless to say, the $3.6 trillion muni bond market breezed past the 6.97% return generated by investment grade corporate bonds and 4.6% return delivered by the safe-haven U.S. treasuries. In fact, this outperforming corner of the bond market has not fallen behind even in a single month of 2014. This was in stark contrast to a lackluster performance in 2013 when the space crumbled thanks to poor financial health of Detroit and Puerto Rico as well as rising rate woes. Behind the Surge Municipal bonds are an excellent choice for investors seeking a steady stream of tax free income. Usually the interest income from munis is exempt from federal tax and may also not be taxable per state laws, making it especially attractive for investors in the high tax bracket looking to reduce their tax liability. Apart from investors’ desire for a tax-shelter, the demand-supply imbalance, improving fiscal health of many municipal bond issuers and a defensive sentiment prevailing in the market on sluggish global recovery made for a rewarding combination. As per Janney Montgomery , U.S. municipal-bond issuance will decline each year through 2017 to as low as $175 billion. Investor’s appetite for munis pushed the yields to multi-month lows. If this was not enough, the space is presently undervalued. A recent Bloomberg article stated that muni bonds almost reached the ‘cheapest’ valuation as compared to U.S. treasuries in 2014. The flight to safety mode led investors to grasp Treasuries quickly making munis an undervalued investment proposition. A Bet for 2015 Too With the deadline for income tax return filing coming closer, demand for municipal bonds should be on a roll in the New Year as well. Investors should note that munis are safer bets compared to corporate bonds and yield better than treasuries. With the Fed insisting to take a ‘patient’ stance on the rate hike issue, the higher yield nature of the munis should keep it in a straight up trajectory. ETF Plays Thanks to the muni boom, as much as $13.4 billion of assets were in muni ETFs’ as of September 30, an all-time high. Given the bright prospects of the muni space, let’s look at some of the top performing ETFs in the space. These could be a good way to target the best of the segment and these might be interesting selections for 2015 as well: Market Vectors CEF Municipal Income ETF ( XMPT ) This overlooked choice looks to track the S-Network Municipal Bond Closed-End Fund Index. The product is composed of shares of municipal closed-end funds listed in the U.S. that are principally engaged in asset management processes designed to produce a federally tax-exempted annual yield. Notably, closed-end products are best-suited for those who seek higher income. The product charges165 bps in fees and has mustered an asset base of $39 million. The fund is up 17.8% year to date and 0.6% in the last one month (as of December 31, 2014). The fund has a dividend yield of 5.58% as of the same date. SPDR Nuveen Barclays Build America Bond ETF ( BABS ) This is a long-term muni bond ETF and thus scored the best in 2014 thanks to the flattening of the yield curve. The product looks to track the Barclays Build America Bond Index, which is a division of the Barclays Taxable Municipal Bond Index. The product has amassed about $113.2 million in assets and charges about 35 bps in fees. The fund is up 21.3% this year and 2.23% in the last one month (as of December 31, 2014). The fund has a dividend yield of 3.61%. Market Vectors Long Municipal Index ETF ( MLN ) This fund looks to track the Barclays Capital AMT-Free Long Continuous Municipal Index. This Index intends to mainly measure the performance of long-duration U.S. muni bonds with nominal maturity of at least 17 years. Income from MLN is free of the federal tax burden and alternative minimum tax. The ETF has managed an asset base of about $93.5 million and has an expense ratio of 0.24%. MLN is up 17% so far this year and up 1.82% in the last one month. The fund has a dividend yield of 3.86%.